



IN VITRO ANTIOXIDANT ACTIVITY, IN SILICO MOLECULAR DOCKING AND ADME PREDICTION STUDIES OF A SERIES OF AMINO SUBSTITUTED β -CARBOLINES

Alivelu Samala^{1,3,*}, Srinivasa Murthy M.² and Krishna Mohan Gottumukkala³

¹Department of Pharmaceutical Chemistry, Holy Mary Institute of Technology and Science- College of Pharmacy, Bogaram-Keesara, Medchal, Telangana, India, 501301.

²Department of Pharmaceutical Chemistry, Vignan Institute of Pharmaceutical sciences, Near Ramoji Film City, Deshmukhi, Yadadri-Bhuvanagiri, Telangana, India, 508284.

³Centre for Pharmaceutical Sciences, Inst of Science and Technology, JNT University Hyderabad, Kukatpally, Telangana, India, 500085.



*Corresponding Author: Alivelu Samala

Department of Pharmaceutical Chemistry, Holy Mary Institute of Technology and Science- College of Pharmacy, Bogaram-Keesara, Medchal, Telangana, India, 501301.

Article Received on 21/06/2024

Article Revised on 11/07/2024

Article Accepted on 31/07/2024

ABSTRACT

In the present study, we report the in vitro antioxidant activity, in silico molecular docking and ADME prediction studies of a series of aminosubstituted β -Carbolines. Antioxidant activity was tested by using 2,2-Diphenyl-1-picrylhydrazyl (DPPH) assay. Among the tested bioactive products, β CD7 and β CD3, were shown promising antioxidant activity (IC_{50} values 42.79 ± 0.38 μ g/ml and 43.13 ± 0.42 μ g/ml respectively) compared with the standard drug ascorbic acid (IC_{50} value 34.34 ± 0.21 μ g/ml). As a result, we used molecular docking experiments against human peroxiredoxin 5 for β CDs with possible binding energies (-7.01 Kcal/mol to -5.30 Kcal/mol) to investigate repressive mechanisms and reflect a good predicted interactions between the ligand and protein. Further, ADME properties were evaluated in silico by using Lipinski's parameters, topological polar surface area and percentage absorption. Based on the in vitro and in silico studies a series of β CDs may be helpful for further studying SAR and designing more potent antioxidants.

KEYWORDS: β -Carboline, Antioxidant activity, Molecular docking, ADME properties, Lipinski's parameters.

1 INTRODUCTION

β -Carbolines (Pyrido[3,4-b]indole), both natural and synthetic derivatives, have a significant influence on chemical biology and drug discovery. Harmalin was the first known β -Carboline alkaloid, isolated from *Peganum harmala* in 1841. The presence of β -Carbolines in nature

is usual due to its simple biogenesis from tryptophan/tryptamine. It is an important pharmacophore with a wide range of therapeutic activities. β -Carbolines (β Cs, A), 3, 4-Dihydro- β -Carbolines (DH β Cs, B), and 1,2,3,4-Tetrahydro β -Carbolines (TH β Cs, C) are the three common types of β Cs (1-9) (**Figure 1**).




Figure 1: The basic structural units of β Cs (A), DH β Cs (B) and TH β Cs (C).

Living organisms produces Reactive oxygen species (ROS) as a result of normal cellular metabolism. They function in physiological cell processes at low to moderate concentrations, but at high concentrations, they cause adverse modifications to cell components (10-15). "Oxidative stress" is defined as a change in the oxidant/antioxidant equilibrium in favour of oxidants.

Chronic disorders such as neurodegenerative diseases, diabetes, cardiovascular disease, and cancer all have oxidative stress as a primary factor to their pathogenesis (16-19). Antioxidants are substances that counteract the effects of oxidants. Koteppa Pari *et al* (20), Moura DJ *et al* (21) and Nicole *et al* (22) were some of the previously reported β -Carboline derivatives as antioxidants.

The synthesis and antibacterial activity of a series of title compounds (β CD1- β CD10) were previously reported (**Figure 2**) (23). The potential of β Cs and the significance of the search for redesigned antioxidant agents led our group to an ongoing study of this group of

compounds. As a result, we report in-vitro antioxidant assessment and molecular docking studies of β -Carbolines in this work. In addition, the Lipinski's parameters, TPSA, and % ABS were explored in silico to study the ADME properties of β CDs.











 N-methyl-9H-pyrido[3,4-b]indol-6-amine (βCD1)	 N-ethyl-9H-pyrido[3,4-b]indol-6-amine (βCD2)
 N-propyl-9H-pyrido[3,4-b]indol-6-amine (βCD3)	 N-isopropyl-9H-pyrido[3,4-b]indol-6-amine (βCD4)
 N-butyl-9H-pyrido[3,4-b]indol-6-amine (βCD5)	 N-isobutyl-9H-pyrido[3,4-b]indol-6-amine (βCD6)
 N-phenyl-9H-pyrido[3,4-b]indol-6-amine (βCD7)	 N-(4-nitrophenyl)-9H-pyrido[3,4-b]indol-6-amine (βCD8)
 N-(p-tolyl)-9H-pyrido[3,4-b]indol-6-amine (βCD9)	 N-(furan-2-ylmethyl)-9H-pyrido[3,4-b]indol-6-amine (βCD10)

Figure 2: β -Carboline derivatives (β CD1- β CD10).

2 MATERIALS AND METHODS

All of the reagents were purchased from commercial suppliers. The well-known Pictet Spengler reaction was used to create a new series of β -Carboline derivatives. Antioxidant properties of β CDs were determined spectrophotometrically.

2.1 Biological evaluation

2.1.1 Antioxidant activity

The DPPH assay method (24), radical scavenging DPPH has a violet coloring, the intensity of which decreases in the presence of antioxidants proportionally to the ability to “sweep off” free radicals by the tested compound. About 2 ml of different doses of β CDs or standard were added to the 2 ml of DPPH solution (0.1 mM). After 30 minutes of incubation at 37° c in the dark, the absorbance

was measured at 517 nm and all tests were performed in triplicate. Further, to establish the antiradical potential, Graphpad prism 8 statistical linear regression analysis program was utilized in the 95% confidence interval ($p < 0.001$). **Table 1 and Figure 3** summarizes the calculated IC_{50} values.

$$\% \text{ Inhibition} = (C_{ab} - S_{ab} / C_{ab}) \times 100.$$

(C_{ab} – Absorbance of control; S_{ab} – Absorbance of sample).

2.2 Computational studies

2.2.1 Computational tools

At first, the ligand structures of title compounds (β CD1- β CD10) were generated using Chem Draw 12.0 software to execute all in- silico studies.

2.2.2 Molecular docking

The goal of molecular docking studies is to predict a ligand's predominant binding mode (s) to a protein (macromolecule). In-silico antioxidant molecular docking was done using the Autodock vina to better understand the inhibitory mechanism as well as the mechanism of interrelatedness of the produced molecules.

The protein model will represent the crystal structure of human peroxiredoxin 5 (PDB code 1HD2) with a resolution of 1.5Å. Water molecules were removed from the protein, polar hydrogen's were added, kolman united atom charges were assigned, and the file was saved in .pdbqt format. Chemdraw 12.0 software was used to draw 2D structure and converted into 3D structure by using Chemdraw 3D and energy minimization carried out by MM2 for each ligand and saved as sdf format later by using Open Bebal software converted into suitable

formats. Molecular docking analysis performed by PyMol and Biovia discovery studio.

2.2.3 Study of ADME properties

Using the Molinspiration tools (<http://www.molinspirations.com>), an in-silico study of the ADME characteristics of β CDs were carried out by investigating their lipinski's parameters, TPSA and % ABS calculations (25-27).

3 RESULTS AND DISCUSSION

3.1 Antioxidant activity

The antiradical activity of the 10 β CDs was determined by using the DPPH assay, and their IC_{50} values (The concentration of the compounds that caused 50 % inhibition) were calculated (**Table 1 & Figure 3**). β CD7 and β CD3 were showed good DPPH scavenging activity with IC_{50} values 42.79 ± 0.38 μ g/ml and 43.13 ± 0.42 μ g/ml respectively which are comparable to standard drug ascorbic acid (IC_{50} value 34.34 ± 0.21 μ g/ml).

Table 1: Antioxidant activity of DPPH scavenger radical for β CDs and Ascorbic acid.

Compound	IC_{50} (Mean $\pm$ SEM) μ g/ mL
β CD1	55.00 ± 1.39
β CD2	49.97 ± 0.62
β CD3	43.13 ± 0.42
β CD4	50.69 ± 0.10
β CD5	56.35 ± 4.03
β CD6	54.69 ± 1.15
β CD7	42.79 ± 0.38
β CD8	50.80 ± 0.85
β CD9	55.74 ± 4.27
β CD10	56.08 ± 2.98
AA	34.34 ± 0.21




Figure 3: Antioxidant activity of β CDs and Ascorbic acid.

3.2 Molecular docking studies

Molecular docking studies were performed on β CD1 - β CD10 to substantiating the in vitro results with in -silico studies. This research will focus on the enzyme 1HD2. The binding energies of the tested β CDs to the target macromolecule 1HD2 ranged from -7.01 Kcal/mol to -5.30 Kcal/mol. β CD8 (-7.01 Kcal/mol), β CD7 (-6.83

Kcal/mol), β CD9 (-6.61 Kcal/mol), and β CD10 (-6.51 Kcal/mol) were shown to have a high affinity for 1HD2.

Even yet, there was not always a link between the results of the in silico and in vitro studies. Despite the fact that β CD1 (-6.01 Kcal/mol), β CD6 (-6.0 Kcal/mol), β CD9 (-6.61 Kcal/mol), β CD10 (-6.51 Kcal/mol) and β CD8 (-

7.01 Kcal/mol) had high binding affinity for 1HD2 (-6.80 Kcal/mol) showed low antioxidant activity.

Furthermore, the interactions in β CD7 and β CD3 binding energies matched the in vitro DPPH assay experimental findings from antioxidant studies. The antioxidant

properties of β CDs may be attributed to contact between the β CDs and the 1HD2, according to in vitro evidence and molecular docking studies. **Table 2** shows the docking results, and **Figure 4, 5 & 6** shows the receptor interactions of the β CD7 & β CD3.

Table 2: Molecular docking studies of β CDs.

Compound	Dock score (Kcal/mol)	No. of Hydrogen bonds	Interacting amino acids	H-Bond distance (Å)
β CD1	-6.01	0	-	-
β CD2	-5.50	1	GLY 85	3.06
β CD3	-5.91	2	GLY 85, GLU 91	2.25, 2.81
β CD4	-5.72	1	VAL 94	2.17
β CD5	-5.30	0	-	-
β CD6	-6.0	0	-	-
β CD7	-6.83	2	ALA 90, VAL 94	2.44, 2.34
β CD8	-7.01	1	GLU 91	2.73
β CD9	-6.61	0	-	-
β CD10	-6.51	0	-	-
AA (Ascorbic acid)	-6.80	4	GLU 16, ARG 86, ALA 90, GLU 91	2.2, 3.0, 2.63, 2.63




Figure 4: 3D Receptor positioning of the most active candidates β CD7 (left side) & β CD3 (right side).




Figure 5: Binding mode of β CD7 into the active site of 1HD2 (left side: 3D interactions & right side: 2D interactions).




Figure 6: Binding mode of β CD3 into the active site of 1HD2 (left side: 3D interactions & right side: 2D interactions).

3.3 Study of ADME properties

Our results (Table 3) revealed that the β CDs: i) MW < 500 (197.24-304.3); ii) nHBA < 10 (3-6); iii) nHBD < 5 (2); iv) Lipophilicity < 5 (2.21-4.79) and v) nr < 5 (1-4).

All parameters are in agreement with lipinski's rule and the calculated %ABS of all β CDs ranged between 79.15 % and 94.96 %, indicating that these compounds have good permeability in the cellular plasma membrane.

Table 3: % ABS, TPSA, Lipinski's parameters, Log S for compounds β CD1- β CD10.

Com	%Abs	TPSA	Log P	Lipinski's parameters					
				MW	nHBA (ON)	nHBD (OHNH)	Nr	Nv	Log S
β CD1	94.96	40.71	2.21	197.24	3	2	1	0	3.62
β CD2	94.96	40.71	2.58	211.27	3	2	2	0	3.84
β CD3	94.96	40.71	3.08	225.29	3	2	3	0	4.16
β CD4	94.96	40.71	3.54	225.29	3	2	2	0	4.16
β CD5	94.96	40.71	3.64	239.32	3	2	4	0	4.37
β CD6	94.96	40.71	3.33	239.32	3	2	3	0	4.48
β CD7	94.96	40.71	4.34	259.31	3	2	2	0	4.99
β CD8	79.15	86.53	4.3	304.31	6	2	3	0	-5
β CD9	94.96	40.71	4.79	273.34	3	2	2	0	5.27
β CD10	90.42	53.85	2.86	263.3	4	2	3	0	3.77

Note- %ABS= $109 - (0.345 \times \text{TPSA})$; TPSA= Topological Polar Surface Area; LogP= Octanol-Water partition coefficient; MW= Molecular weight; nHBA (ON) = Number of hydrogen bond acceptors; nHBD (OHNH) = Number of hydrogen bond donors; nr = Number of rotatable bonds; nv = Number of violations; LogS= Solubility

4. CONCLUSION

All the β CDs were tested for the antioxidant properties by DPPH assay. Among the tested compounds β CD7 and β CD3 were found to be most effective antioxidants. Furthermore, molecular docking studies with protein 1HD2 for receptor-ligand interactions were conducted, revealing that all of the β CDs had a high binding affinity to 1HD2. Finally, an in-silico study identified β CDs as potential candidates for new drugs.

ACKNOWLEDGMENTS

Author is grateful to Principal and Management of Holymary Institute of Technology and Science (College of Pharmacy) for providing research facilities.

Conflict of interest: The authors declare no conflict of interest.

Financial support: None.

Ethics statement: None.

REFERENCES

- Cao R, Peng W, Wang Z, Xu A. β -Carboline alkaloids: Biochemical and Pharmacological functions. Current medicinal chemistry, 2007; 14(4): 479–500.
- Yao K, Zhao M, Zhang X, Wang Y, Li L, Zheng M, Peng, SA. A class of oral N-[(1S,3S)-1-methyl-1,2,3,4-tetrahydro- β -carboline-3-carbonyl]-N-(aminoacid-acyl) hydrazine: Discovery, synthesis, in

- vitro anti-platelet aggregation/ in vivo anti-thrombotic evaluation and 3D QSAR analysis. *European journal of medicinal chemistry*, 2011; 46(8): 3237-3249.
3. Bi W, Bi Y, Xue P, Zhang Y, Gao X, Wang Z, Li M., et al. A new class of β -carboline alkaloid-peptide conjugates with therapeutic efficacy in acute limb ischemia/reperfusion injury. *European journal of medicinal chemistry*, 2011; 46(5): 1453-1462.
 4. Liu J, Jiang X, Zhao M, Zhang X, Zheng M, Peng I, Peng S. A class of 3S-2-aminoacyltetrahydro beta carboline-3-carboxylic acids: Their facile synthesis, inhibition for platelet activation, and high in vivo anti-thrombotic potency. *Journal of medicinal chemistry*, 2010; 53(8): 3106-3116.
 5. Costa EV, Pinheiro MLB, De Souza ADL, Barison A, Campos FR, Valdez RH, Ueda-Nakamura T, Dias BP, Nakamura CV. Trypanocidal activity of oxoaporphine and pyrimidine- β -carboline alkaloids from the branches of *Annona foetida* Mart. (Annonaceae). *Molecules*, 2011; 16(11): 9714-9720.
 6. Polanski W, Reichmann H, Gille G. Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl- β -carboline: A new anti-Parkinson drug. *Expert review of neurotherapeutics*, 2011; 11(6): 845-860.
 7. Valdez RH, Tonin LTD, Ueda-Nakamura T, Silva SO, Dias BP, Kaneshima EN, Yamada-Ogatta SF, Yamauchi LM, Sarrajiotto MH, and Nakamura CV. In vitro and in vivo trypanocidal synergistic activity of N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro- β -carboline-3-carboxamide associated with benzimidazole. *Antimicrobial agents and chemotherapy*, 2012; 56(1): 507-512.
 8. Franciele C, Savariz Anelise SN, Formagio Valéria A, Barbosa, Mary Ann Foglio, João, E, Carvalho, Marta CT, Duarte, Benedito P. Dias Filhoc, Maria Helena Sarrajiotto. Synthesis, Antitumor and Antimicrobial Activity of Novel 1-Substituted Phenyl-3-[3-alkylamino (methyl)-2-thioxo-1,3,4-oxadiazol-5-yl] b-Carboline Derivatives. *Journal of the Brazilian chemical society*, 2010; 21(2): 288-298.
 9. Alivelu Samala, Srinivasa Mutrhy M, Krishna Mohan Gottumukkala. A Comprehensive Review on recent advances in synthesis & pharmacotherapeutic potential of β -Carbolines. *Research journal of pharmacy and technology*, 2018; 11(8): 3547-3560.
 10. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. *Chemico-biological interactions*, 2006; 160(1): 1-40.
 11. Halliwell B, Gutteridge JMC. *Free Radicals in Biology and Medicine*. 3rd ed. New York: Oxford University Press, 1999; 1-25.
 12. Marnett LJ. Lipid peroxidation—DNA damage by malondialdehyde. *Mutation research*, 1999; 424(1-2): 83-95.
 13. Siems WG, Grune T, Esterbauer H. 4-Hydroxynonenal formation during ischemia and reperfusion of rat small-intestine. *Life sciences*, 1995; 57(8): 785-789.
 14. Stadtman ER. Role of oxidant species in aging. *Current medicinal chemistry*, 2004; 1(19): 1105-1112.
 15. Wang M, Dhingra K, Hittelman WN., Liehr JG, deAndrade M, and Li DH. Lipid peroxidation-induced putative malondialdehyde-DNA adducts in human breast tissues. *Cancer epidemiology biomarkers & prevention*, 1996; 5(9): 705-710.
 16. Jenner P. Oxidative stress in Parkinson's disease. *Annals of neurology*, 2003; 53(S3): S26-S36.
 17. Lyras L, Cairns N.J, Jenner A, Jenner P, Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. *Journal of neurochemistry*, 1997; 68(5): 2061-2069.
 18. Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. *Current medicinal chemistry*, 2001; 8(7): 721-738.
 19. Toshniwal PK, and Zarling EJ. Evidence for increased lipid peroxidation in multiple sclerosis. *Neurochemical research*, 1992; 17(2): 205-207.
 20. Koteppa Pari C, Sivakama S, Sushil C, Dorairajan B. β -Carbolines accumulate in human tissues may serve a protective role against oxidative stress. *The American society for biochemistry and molecular biology*, 2000; 275(4): 2455-2462.
 21. Moura DJ, Richter MF, Boeira JM, Pegas Henriques JA, Saffi. Antioxidant properties of beta-carboline alkaloids are related to their antimutagenic and antigenotoxic activities. *Mutagenesis*, 2007; 22(4): 293-302.
 22. Sudzukovic N, Schinnerl J, Brecker L. Phytochemical meanings of tetrahydro- β -carboline moiety in strictosidine derivatives. *Bioorganic and medicinal chemistry*, 2015; 24(4): 588-595.
 23. Alivelu Samala., Srinivasa Mutrhy M, Krishna Mohan Gottumukkala. Synthesis and antibacterial screening of new N-Substituted-9H- β -carboline-6-amine derivatives. *International journal of research in pharmaceutical sciences*, 2020; 11(3): 4146-4151.
 24. Shakawat H, Fatema A, Abid N, Nazia Hassan. In Vitro Antioxidant, Cytotoxicity and In Vivo Neuropharmacological Effects of IPOMOEIA PES-TIGRIDIS. *European journal of pharmaceutical and medical research*, 2017; 4(12): 522- 529.
 25. Lipinski CA, Lombardo F, Dominy BW, Freeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced drug delivery reviews*, 2001; 46(1-3): 3-26.
 26. Ertl P. Calculations of molecular properties and bioactivity score, available online: <http://www.molinspirations.com>).

27. Yuan H, Zhao, Michael H, Abraham, Joelle Le, Anne Hersey, Chris N, Cooper. Rate – limited steps of human oral absorption and QSAR studies. *Pharmaceutical Research*, 2002; 19(10): 1446-1457.